Pharma channel feed

Can­cer Re­search UK launch­es new Lon­don Cen­tre, in­fus­ing £14M in­to bio­ther­a­peu­tics work from lead­ing in­sti­tutes

7 years ago
R&D

CRISPR pays to part­ner with Vi­a­Cyte on an off-the-shelf gene-edit­ing ap­proach to cur­ing di­a­betes

7 years ago

The FDA lifts a par­tial hold on Mer­sana's top drug -- and then its shares crater

7 years ago

An­timi­cro­bial re­sis­tance: FDA dis­cuss­es re­im­burse­ment re­forms

7 years ago

Te­va gets a bad­ly need­ed win: FDA OKs their run­ner-up CGRP mi­graine drug, with Eli Lil­ly trail­ing be­hind

7 years ago

Re­gen­eron maps a dra­mat­ic ex­pan­sion with 1,500 new jobs — and that makes NY’s gov­er­nor very hap­py

7 years ago

The lat­est tem­pest over a dra­mat­ic drug price hike riles two pow­er­ful sen­a­tors — who can't ac­tu­al­ly do any­thing about it

7 years ago

As­traZeneca grabs an FDA OK for its new leukemia drug, to be mar­ket­ed as Lu­mox­i­ti

7 years ago

Phar­ma com­pa­nies out­per­form in­sti­tu­tions in Eu­ro­pean clin­i­cal tri­al re­port­ing amid prob­lem­at­ic over­all trends — Ox­ford study

7 years ago

SEC charges that hedge fund man­ag­er (and priest) re­lied on false claims to pro­mote a Lig­and short at­tack

7 years ago
People

BIO, Al­ler­gan and Roche call for FDA flex­i­bil­i­ty with pa­tient ex­pe­ri­ence da­ta

7 years ago

Skirt­ing a group of pi­o­neers, Gilead part­ners with gene-edit­ing up­start Pre­ci­sion Bio in hunt to cure hep B

7 years ago

A Mar­tin Shkre­li wannabe de­fends a big spike in drug price and earns a Twit­ter lash­ing from the FDA's com­mish

7 years ago

Mer­ck her­alds a rare Big Phar­ma suc­cess for an­tibi­ot­ic PhI­II, but it’s al­so a cau­tion­ary tale about the mar­ket

7 years ago
R&D

No­var­tis makes it of­fi­cial: Al­con is mov­ing its HQ from Texas to Gene­va ahead of a spin­off

7 years ago

Acor­da shares crater af­ter ap­peals court dash­es re­main­ing hopes for sal­vaging Ampyra patents — gener­ics loom

7 years ago

The Broad wins an­oth­er — per­haps fi­nal — bat­tle in the war over Feng Zhang's CRISPR patents

7 years ago
People

Am­i­cus chief John Crow­ley is snubbed at the FDA on his lat­est pitch for quick drug re­view. He'll be back, but an­a­lyst sees big de­lay

7 years ago

Re­volv­ing door be­tween in­dus­try and FDA con­tin­ues to spin

7 years ago
People

The pain won't stop. GSK ends the week with a slap­down on its Nu­cala ap­pli­ca­tion for COPD

7 years ago

GSK’s flop Poti­ga is picked up and head­ed for a quick makeover for pe­di­atric epilep­sy. Any bets on the prospec­tive price?

7 years ago

As­traZeneca, Am­gen roll up a 'break­through' at the FDA in hot pur­suit of a po­ten­tial game chang­er in asth­ma

7 years ago

Ham­mered hard by a sur­pris­ing FDA re­jec­tion, Io­n­is spin­out Akcea of­fers an ex­pla­na­tion and then chops 1-in-10 staffers

7 years ago
R&D

GSK chops 650 jobs, vow­ing to shift more mon­ey to a weak R&D ef­fort

7 years ago
First page Previous page 288289290291292293294 Next page Last page
A service from the Financial Times